EMA/419263/2020

European Medicines Agency decision

P/0367/2020

of 9 September 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for relamorelin (EMEA-002323-PIP02-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0367/2020

of 9 September 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for relamorelin (EMEA-002323-PIP02-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Allergan Pharmaceuticals International Limited on 15 July 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 July 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision refusing a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for relamorelin, solution for injection, age-appropriate solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for relamorelin, solution for injection, age-appropriate solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for relamorelin, solution for injection, age-appropriate solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby refused.

Article 4

This decision is addressed to Allergan Pharmaceuticals International Limited, Clonshaugh Business & Technology Park, D17 E400 - Dublin 17, Ireland.

EMA/PDCO/260774/2020 Corr
Amsterdam, 24 July 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and on the refusal of a waiver

EMEA-002323-PIP02-19

Scope of the application

Active substance(s):

Relamorelin

Condition(s):

Treatment of gastroparesis

Pharmaceutical form(s):

Solution for injection

Age-appropriate solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Allergan Pharmaceuticals International Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Allergan Pharmaceuticals International Limited submitted for agreement to the European Medicines Agency on 15 July 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 20 August 2019.

Supplementary information was provided by the applicant on 27 March 2020. The applicant proposed modifications to the paediatric investigation plan and to the waiver.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to refuse the granting of a waiver in accordance with Article 13 of said Regulation, for some of the subsets of the paediatric population and the above mentioned condition(s) as it does not meet the grounds detailed in Article 11(1) of said Regulation.

   The Norwegian Paediatric Committee members agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

1.1. Condition:

Treatment of gastroparesis

The request of the waiver applied to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, age-appropriate solution for injection; subcutaneous use.

The waiver request does not provide evidence to support the following grounds set out in Article 11(1) of Regulation (EC) No 1901/2006 that:

- the specific medicinal product is likely to be ineffective or unsafe in the paediatric population;
- the disease or condition for which the specific medicinal product is intended occurs only in adult populations;
- the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

Because:

- the PDCO disagreed with the applicant(s)' argumentation that the specific medicinal product is likely to be ineffective or unsafe in the specific age group;
- the disease or condition for which the specific medicinal product is intended, does occur in that subgroup of the paediatric population(s);
- measures would be justified by the expected therapeutic benefit and clinical trials may be feasible;
- the specific medicinal product may represent a significant therapeutic benefit as the needs are not met;
- clinical studies may fulfil a therapeutic need of the paediatric population.

The waiver request is therefore refused by the PDCO.

2. Paediatric investigation plan

2.1. Condition:

Treatment of gastroparesis

2.1.1. Indication(s) targeted by the PIP

Treatment of gastroparesis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection (in a multi-use pen injector device)

Age-appropriate solution for injection (in a multi-use pen injector device)

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1:** Development of an age-appropriate solution of injection, in a multi-use pen injector device, for subcutaneous administration in children from birth to less than 12 years of age.
Non-clinical studies	2	**Study 2:** Definitive juvenile toxicity study in rats from post-natal day 45 onwards, to determine the safety of relamorelin in juvenile rats. **Study 3:** Definitive juvenile toxicity study in rats from equivalent to 2 years to less than 12 years, to determine the safety of relamorelin in juvenile rats.
Clinical studies	4	**Study 4:** Randomised, double-blinded, placebo-controlled study to evaluate the safety and efficacy of relamorelin in adolescents (12 to less than 18 years of age) with gastroparesis. **Study 5:** Multiple crossover study to evaluate safety and efficacy of relamorelin in paediatric patients (6 to less than 12 years of age) with gastroparesis. **Study 6:** Multiple crossover study to evaluate safety and efficacy of relamorelin in paediatric patients (2 to less than 6 years of age) with gastroparesis. **Study 7:** Open-label, uncontrolled study to evaluate safety and activity of relamorelin in neonates and toddlers (birth to less than 2 years of age) with gastroparesis.
Extrapolation, modelling and simulation studies	2	**Study 8:** Population pharmacokinetic (PK) model with data from Phase 1, Phase 2a and Phase 2b studies in adult healthy volunteers and diabetic gastroparesis patients, and sparse sampling data from adult confirmatory studies, to evaluate the use of relamorelin in gastroparesis, in children from 2 to less than 18 years of age. **Study 9:**

		Partial extrapolation of efficacy data from the adult studies in conjunction with PK data and common gastroparesis symptoms, to support the use of relamorelin in gastroparesis, in children from 2 to less than 18 years of age.
Other studies	N/A	Not applicable
Other measures	N/A	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2030
Deferral for one or more measures contained in the paediatric investigation plan:	Yes